Current Editions
Series A companies: Biotech’s class of 2025
With numbers flat vs 2024, the decline seems over — another sign the thaw is real
Finance
Product Development
Sanofi misses in Fabry: Is it time to move on from GCS inhibition in the indication?
Different points of pathway intervention in Gaucher vs. Fabry may be
Editor's Commentary
Compounded Wegovy is more than a scam — it threatens innovation
FDA must prevent mass compounding of approved drugs to protect patients and investment in innovative drugs
Finance
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report
Plus: Veradermics, SpyGlass enjoy first-day bumps; Generate Bio files for NASDAQ listing
Management Tracks
McKinsey vet Franck Le Deu joins Nisa Leung’s new fund; plus C-suite shuffle at Bicycle
Management moves for the week of Feb. 2-6
BioCentury ISSN 1097-7201